| Large-scale association analyses identify host factors influencing human gut microbiome composition A Kurilshikov, C Medina-Gomez, R Bacigalupe, D Radjabzadeh, J Wang, ... Nature Genetics 53 (2), 156-165, 2021 | 1286 | 2021 |
| Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome EM Hill‐Burns, JW Debelius, JT Morton, WT Wissemann, MR Lewis, ... Movement Disorders 32 (5), 739-749, 2017 | 892 | 2017 |
| Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens ZD Wallen, M Appah, MN Dean, CL Sesler, SA Factor, E Molho, ... npj Parkinson's Disease 6 (1), 11, 2020 | 198 | 2020 |
| Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms ZD Wallen, A Demirkan, G Twa, G Cohen, MN Dean, DG Standaert, ... Nature communications 13 (1), 6958, 2022 | 190 | 2022 |
| Meta-analysis of human genome-microbiome association studies: the MiBioGen consortium initiative J Wang, A Kurilshikov, D Radjabzadeh, W Turpin, K Croitoru, MJ Bonder, ... Microbiome 6 (1), 1-7, 2018 | 150 | 2018 |
| Innate and adaptive immune responses in Parkinson's disease AM Schonhoff, GP Williams, ZD Wallen, DG Standaert, AS Harms Progress in brain research 252, 169-216, 2020 | 101 | 2020 |
| Comparison study of differential abundance testing methods using two large Parkinson disease gut microbiome datasets derived from 16S amplicon sequencing ZD Wallen BMC bioinformatics 22 (1), 265, 2021 | 52 | 2021 |
| Exploring human-genome gut-microbiome interaction in Parkinson’s disease ZD Wallen, WJ Stone, SA Factor, E Molho, CP Zabetian, DG Standaert, ... npj Parkinson's Disease 7 (1), 74, 2021 | 25 | 2021 |
| Oral ingestion of the environmental toxicant trichloroethylene in rats induces alterations in the gut microbiome: Relevance to idiopathic Parkinson's disease NM Ilieva, ZD Wallen, BR De Miranda Toxicology and Applied Pharmacology 451 (2022), 116176, 2022 | 19 | 2022 |
| Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease ZD Wallen, H Chen, EM Hill-Burns, SA Factor, CP Zabetian, H Payami Neurology: Genetics 4 (5), e271, 2018 | 19 | 2018 |
| Population fraction of Parkinson’s disease attributable to preventable risk factors H Payami, G Cohen, CF Murchison, TR Sampson, DG Standaert, ... npj Parkinson's Disease 9 (1), 159, 2023 | 7 | 2023 |
| The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer MK Nesline, V Subbiah, RA Previs, KC Strickland, H Ko, P DePietro, ... Oncology and Therapy, 1-15, 2024 | 5 | 2024 |
| The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer … MK Nesline, P DePietro, M Cooper, S Zhang, S Howarth, ZD Wallen, ... Journal of Clinical Oncology 41 (16_suppl), 6506-6506, 2023 | 3 | 2023 |
| Microbiome-based biomarkers to guide personalized microbiome-based therapies for Parkinson’s disease H Payami, TR Sampson, CF Murchison, ZD Wallen medRxiv, 2024.04. 03.24305273, 2024 | 1 | 2024 |
| 87 Distinctions in Tumor Microenvironment Between PD-L1 Positive versus Negative Head and Neck Squamous Cell Carcinoma (HNSCC) KS Saini, HC Ko, ZD Wallen, MF Green, KC Strickland, RA Previs, ... Radiotherapy and Oncology 192, S20-S22, 2024 | 1 | 2024 |
| Large-scale association analyses identify host factors influencing human gut microbiome composition A Kurilshikov, C Medina-Gomez, R Bacigalupe, D Radjabzadeh, J Wang, ... bioRxiv, 2020.06. 26.173724, 2020 | 1 | 2020 |
| Alpha synuclein overexpression can drive microbiome dysbiosis in mice TR Sampson, ZD Wallen, WJ Won, DG Standaert, H Payami, AS Harms Scientific Reports 15 (1), 4014, 2025 | | 2025 |
| Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers RA Previs, KC Strickland, Z Wallen, H Ko, M Green, M Cooper, E Lyon, ... Gynecologic Oncology 192, 102-110, 2025 | | 2025 |
| Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel … ZD Wallen, MK Nesline, M Tierno, A Roos, E Schnettler, H Husain, ... Frontiers in Oncology 14, 1473327, 2024 | | 2024 |
| 10 Immune gene expression-based biomarkers of the tumor immune microenvironment associated with variable response to immunotherapies in syngeneic mouse models of human cancers ZD Wallen, KC Strickland, S Barnes, S Pabla, MK Nesline, JM Conroy, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |